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Department of Family & Community Medicine
• 90% of adults 
with CKD are 
unaware of their 
condition
• 40% of adults 
with severe CKD 




• Review screening guidelines for CKD
• Review staging of CKD
• Outline diagnostic approach 
• Review primary care management 
• Understand indications for referral to specialty care
We will NOT cover
• Diagnosis or management of AKI
• In-depth management of advanced/end-stage disease
• Management of patients with renal transplant
• Management of CKD in pediatric patients
• Pharmacologic adjustments in CKD
• IV contrast prophylaxis or management
Definition
• Abnormal kidney structure or function
• GFR <60 or urinary albumin >30 mg/day
• Must be present for >3 months
Chronic kidney disease is not a primary diagnosis
Role of the PCP
• Screening
• Slowing disease progression
• Preventing complications
Our Patient
WH is a 55-year-old male presenting to clinic for an initial 
visit to establish care. He reports a past medical history of 
type 2 diabetes, hyperlipidemia, coronary artery disease 
s/p CABG, peripheral vascular disease s/p R BKA, and 
peptic ulcer disease.
VS: BP 125/85 HR 88 T 98F O2 98%
PE: Normal exam with exception of right BKA with prosthesis
The Plan
WH brought his medication bottles with him. They include: 








He has not seen a PCP in some time. What labs or screening do 
you want to order?
Who do we screen?
Universal screening is not recommended 
“The U.S. Preventive Services Task Force found 
insufficient evidence to assess the balance of benefits and 
harms of screening for chronic kidney disease in the 
general population, and the American College of 
Physicians recommends against screening asymptomatic 
adults without risk factors.”
Screening At-Risk Populations
Diabetes and hypertension are the leading causes 
of kidney failure in the US, accounting for 75% of 
new cases of CKD
Additional risk factors: age >60 yrs, family history of kidney 
disease, cardiovascular disease, obesity
Screening Method
• Measure eGFR and proteinuria
• Urine Albumin/Creatinine ratio






Previous albumin/Cr: 354 mg/g 1 year ago

Initial Workup
• Thorough history and physical
• Exposure to nephrotoxins
• Blood pressure, diet, weight history
• Electrolytes
• Lipids, A1c












• Not routinely indicated
• Ultrasound when there is a history of urinary tract 
stones or obstruction, frequent UTIs, or a family 
history of polycystic kidney disease
Role of the PCP
• Screening
• Slowing disease progression
• Preventing complications
RAS Blockade
• ACE inhibitors are recommended treatment for 
nondiabetic CKD over ARBs
• Use of an ACE inhibitor in CKD is associated with a 
31% reduction in end stage renal disease
Our patient
• WH meets criteria for G2, A3 diabetic kidney disease
• He is already on an ACE inhibitor
• Hgb A1c is 9.2
• Blood pressure is well controlled
• Which other medication would he benefit from?
Treatment in Diabetic Kidney Disease
• ACE inhibitors + ARBs are equally beneficial at slowing 
nephropathy in diabetic CKD
• Dual ACE inhibitors + ARBs are not beneficial and have 
harmful effects




• At risk populations: screen annually
• DKD: every 3-6 months
• CKD 3: twice yearly
• CKD 4: four times yearly
PCP Management
• Blood pressure: goal <130/80 (per ACC/AHA 2017 
guideline)
• Blood glucose: A1c goal 7%
• Lifestyle: smoking cessation
• Diet: recommend <2000 mg sodium daily
Courtesy of AHA
Aspirin & CKD
• Primary prevention: insufficient data to suggest 
empiric use or avoidance of aspirin
• Ongoing clinical trial, Aspirin to Target Arterial Events 
in Chronic Kidney Disease (ATTACK) looking at risk 
reduction of MI and stroke in CKD with daily aspirin use
Our Patient’s Prognosis
• He is on an ACE inhibitor and an SGLT-2 inhibitor was 
started
• Blood pressure is well controlled, weight is in a healthy 
range




Role of the PCP
• Screening
• Slowing disease progression
• Preventing complications
Courtesy of National Kidney Foundation
Screening Intervals for Complications of CKD
METABOLIC BONE DISEASE
• Stage 3: measure calcium, phosphorus, bicarbonate, 
PTH, ALP, and vitamin D once as a baseline
• Stage 4: PTH, calcium, phosphorus every 3 months
• Stage 5: calcium and phosphorus monthly
Anemia
• Usually due to iron deficiency rather than 
erythropoietin deficiency 
• Measure Hgb annually in CKD stage 3
Bone Density
• Stage 1-3a CKD patients can be screened according to 
general osteoporosis guidelines
• CKD is not a specific indication for osteoporosis 
screening, not recommended to test routinely
• Not indicated to routinely prescribe vitamin D without 
known vitamin deficiency
When to refer to Nephrology
• GFR <30
• Significant albuminuria
• Rapid drop in GFR
• Unexplained or persistent hematuria
• Secondary hyperparathyroidism
• HTN refractory to treatment with >4 agents
• Recurrent nephrolithiasis
• Unknown cause of CKD
Summary
• Screen at risk populations (DM + HTN)
• ACE, ACE baby
• Identify the cause and timeline of altered kidney function
• Minimize risk factors: statin, smoking cessation, blood 
pressure, blood sugar
• Monitor for complications starting at CKD stage 3
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